Trial Profile

A Randomised, Double-blind, Placebo-controlled, Phase 2 Trial Investigating the Safety and Efficacy of C21 in Hospitalised Subjects With COVID-19 Infection Not Requiring Mechanical Ventilation

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Buloxibutid (Primary)
Indications COVID-19 respiratory infection; Inflammation; Respiratory insufficiency
Focus Therapeutic Use
Acronyms ATTRACT
Sponsors Vicore Pharma

Most Recent Events

29 Aug 2022 Results assessing short-term C21 treatment decreased the release of NT-proBNP in subjects hospitalised with COVID-19, presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology.
02 Nov 2021 Results presented in the Vicore Pharma Media Release.
25 Oct 2021 Results published in Vicore Pharma Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com